bevacizumab

It is indicated for the treatment of several types of cancers

The focus is on introducing new molecular entities (NMEs) into India, with both parties contributing to accelerate…

The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024

Ranibizumab biosimilar is the company’s seventh biosimilar

The Overall Response Rate (ORR) was 34 per cent (17/50) and ORRs for the low-dose and high-dose groups were 31 per cent and 38 per…

Bevacizumab is a recombinant humanised monoclonal IgG1 antibody that targets vascular endothelial growth factor (VEGF), a key…

Bevacizumab represents the third biosimilar BLA currently filed by Amneal with the FDA

Abevmy 100 and 400 mg is approved for the treatment of metastatic colorectal carcinoma, metastatic breast cancer, non small-cell…

Bevacizumab inhibits the formation of tumor vasculature, thereby inhibiting tumor growth

To complete the application, the agency noted that an inspection of the manufacturing facility is required as a part of the…